Brevan Howard Capital Management’s 10x Genomics TXG Stock Holding History

Brevan Howard Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.98M	Buy	77,803 +51,991	+201%	+$1.36M	0.02%	554
2026 Q1	$548K	Buy	+25,812	New	+$516K	﹤0.01%	1247
2025 Q4	–	Sell	-103,951	Closed	-$1.22M	–	2288
2025 Q3	$1.22M	Buy	103,951 +52,972	+104%	+$691K	0.01%	809
2025 Q2	$590K	Buy	50,979 +36,661	+256%	+$334K	﹤0.01%	1279
2025 Q1	$125K	Sell	14,318 -363	-2%	-$4.58K	﹤0.01%	1035
2024 Q4	$211K	Sell	14,681 -10,929	-43%	-$172K	﹤0.01%	895
2024 Q3	$578K	Buy	+25,610	New	+$529K	﹤0.01%	646
2024 Q2	–	Sell	-11,012	Closed	-$413K	–	1405
2024 Q1	$413K	Sell	11,012 -6,639	-38%	-$292K	﹤0.01%	521
2023 Q4	$988K	Buy	+17,651	New	+$768K	0.01%	237

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's TXG Position: Q2 2026 in Review

Brevan Howard Capital Management increased its 10x Genomics (TXG) stake by 201% in Q2 2026, buying an estimated $1.36M and bringing the position to 77,803 shares worth $2.98M. The position accounts for 0.02% of the portfolio, ranked #554.

Brevan Howard Capital Management first reported a position in TXG in Q4 2023 and has held it in 9 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Brevan Howard Capital Management held 77,803 shares of 10x Genomics worth $2.98M as of Q2 2026.
Brevan Howard Capital Management bought 51,991 10x Genomics shares in Q2 2026, an estimated $1.36M.
10x Genomics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #554 holding.
Brevan Howard Capital Management first reported a position in 10x Genomics in Q4 2023 and has held it in 9 quarters since.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.